U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06416696) titled 'Toripalimab for High-risk Locally Advanced Cervical Cancer' on May 11.
Brief Summary: This phase II clinical study assesses the efficacy and safety of Toripalimab combined with chemoradiotherapy (CRT) followed by Toripalimab maintenance in treating high-risk locally advanced cervical cancer (HR-LACC). Despite CRT being the standard treatment, HR-LACC patients face poor survival outcomes. Toripalimab, a cost-effective PD-1 inhibitor, has shown promise in prior research. The primary endpoint is 2-year progression-free survival, with the study aiming to improve treatment accessibility and patient prognoses in China.
Study Type: Interve...